Instruction for use: Brizoline

Active substance: Xylometazoline

ATX Code R01AA07 Xylometazoline

Pharmacotherapeutic group:

Alpha-adrainomimetiki

decongestant

The nosological classification (ICD-10)

H66.9 Otitis media, unspecified

Chronic otitis, Otitis, otitis media, middle ear infections, Otitis media in children

H68 inflammation and blockage of the ear [Eustachian] pipes

Eustachian, Acute evstahiit, Qatar Eustachian tubes

J01 Acute sinusitis

Inflammation of the sinuses, Inflammatory diseases of the paranasal sinuses, Purulent inflammation of the paranasal sinuses, Infectious-inflammatory diseases of ENT organs, Infection of the sinuses, Combined sinusitis, Exacerbation of sinusitis, Acute inflammation of the paranasal sinuses, Acute bacterial sinusitis, Acute sinusitis in adults, Subacute sinusitis, acute Sinusitis, sinusitis

J04 Acute laryngitis and tracheitis

Cough in diseases of the upper respiratory tract, Laryngitis, acute Laryngitis, tracheitis sharp, pharyngolaryngitis, Infectious-inflammatory diseases of ENT organs

J30 Vasomotor and allergic rhinitis

Allergic rinopatiya, Allergic rhinosinusopathy, Allergic respiratory diseases, Allergic rhinitis, nasal allergy, Seasonal Allergic Rhinitis, Vasomotor rhinitis, Long-allergic rhinitis, Perennial allergic rhinitis, Perennial allergic rhinitis, Year-round or seasonal allergic rhinitis, Year-round allergic rhinitis nature, Rhinitis allergic vasomotor, Exacerbation of pollen allergy in the form of Syndrome rinokonyunktivalnogo, Acute allergic rhinitis, Edema of the nasal mucosa, Edema of the nasal mucosa, Swelling of the mucosa of the nasal cavity, Swelling of the nasal mucosa, Swelling of the nasal mucosa, pollen disease, Permanent allergic rhinitis, rhinoconjunctivitis, rhinosinusitis,rhinosinusopathy, Seasonal allergic rhinitis, Seasonal Allergic Rhinitis, Haymarket rhinitis, Chronic allergic rhinitis, Allergic respiratory diseases

Composition

1 ml of nasal drops comprising Xylometazoline hydrochloride 0.5 mg or 1; in glass or plastic bottles or in plastic bottles-droppers (0.1%) of 10 ml, in a cardboard bundle one bottle or in blisters 5 bottles, in a cardboard unit 1 or 10 packs.

Pharmachologic effect
vasoconstrictor, decongestant.

Turn the alpha-adrenergic receptors.

pharmacodynamics

When applied to the mucous membranes causes vasoconstriction, reducing local congestion and edema, facilitates nasal breathing.

STEP is a few minutes after application and lasts for several hours.

Pharmacokinetics

When applied topically hardly undergoes systemic absorption (creates minimum plasma concentration).

Indications

Acute rhinitis (including viral, bacterial, allergic); sinusitis, evstahiit, otitis media.

Contraindications

Hypersensitivity, arterial hypertension, tachycardia, expressed atherosclerosis, atrophic rhinitis, hyperthyroidism, increased intraocular pressure, angle-closure glaucoma, diabetes, pheochromocytoma, simultaneous reception of MAO inhibitors and the period up to 10 days after the end of their use, the age of 2 years.

Pregnancy and breast-feeding

When pregnancy with caution.

Side effects

Feeling weak burning sensation in the nose and throat, sneezing; with frequent or prolonged use - irritation, hypersecretion, edema, and atrophy of the nasal mucosa; rarely - headache, sleep disturbances, nausea, palpitations and increased blood pressure (an overdose).

Interaction

Sympathomimetics increase the effect.

Brizoline Dosage and Administration

Locally, adults 2-3 drops of 0.1% solution or 1-3 drops (0.05%) in each nostril 2-3 times a day for children 1 drop of 0.05% solution of 1 times a day; After 5-7 days of recommended break for a few days. Should not be applied more than 3 times per day, the duration of drug use no more than 3-5 days. Do not use the drug for more than 2 weeks.

Storage conditions of Brizoline

In a dry, dark place, at a temperature of 15-25 ° C.

Keep out of the reach of children.
Shelf life of Brizoline

2 years.

Do not use beyond the expiration date printed on the package.